ATE88344T1 - Zur behandlung von neurodegenerativen erkrankungen verwendbare kynurensaeurederivate. - Google Patents

Zur behandlung von neurodegenerativen erkrankungen verwendbare kynurensaeurederivate.

Info

Publication number
ATE88344T1
ATE88344T1 AT88307142T AT88307142T ATE88344T1 AT E88344 T1 ATE88344 T1 AT E88344T1 AT 88307142 T AT88307142 T AT 88307142T AT 88307142 T AT88307142 T AT 88307142T AT E88344 T1 ATE88344 T1 AT E88344T1
Authority
AT
Austria
Prior art keywords
compounds
treatment
vivo
acid derivatives
neurodegenerative diseases
Prior art date
Application number
AT88307142T
Other languages
English (en)
Inventor
Paul Leeson
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE88344T1 publication Critical patent/ATE88344T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
AT88307142T 1987-08-12 1988-08-02 Zur behandlung von neurodegenerativen erkrankungen verwendbare kynurensaeurederivate. ATE88344T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878719102A GB8719102D0 (en) 1987-08-12 1987-08-12 Therapeutic agents
EP88307142A EP0303387B1 (de) 1987-08-12 1988-08-02 Zur Behandlung von neurodegenerativen Erkrankungen verwendbare Kynurensäurederivate

Publications (1)

Publication Number Publication Date
ATE88344T1 true ATE88344T1 (de) 1993-05-15

Family

ID=10622209

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88307142T ATE88344T1 (de) 1987-08-12 1988-08-02 Zur behandlung von neurodegenerativen erkrankungen verwendbare kynurensaeurederivate.

Country Status (7)

Country Link
EP (1) EP0303387B1 (de)
JP (1) JPS6466167A (de)
AT (1) ATE88344T1 (de)
CA (1) CA1330660C (de)
DE (1) DE3880396T2 (de)
DK (1) DK449588A (de)
GB (1) GB8719102D0 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (de) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5026700A (en) * 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
IT1232352B (it) * 1989-08-11 1992-01-28 Moroni Flavio Firenze Derivati dell'acido chinurenico ad attivita' sul sistema nervoso centrale, loro preparazione e relative composizioni farmaceutiche
DE69113115T2 (de) * 1990-05-31 1996-06-13 Merck Sharp & Dohme Dioxo-tetrahydrochinolinderivate.
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
EP0573562B1 (de) * 1991-02-27 1996-04-24 Merrell Pharmaceuticals Inc. Dihydrochinolin NMDA Antagonisten
US5606063A (en) * 1991-02-27 1997-02-25 Merrell Pharmaceuticals Inc. NMDA antagonists
GB9109007D0 (en) * 1991-04-26 1991-06-12 Merck Sharp & Dohme Therapeutic method
GB9125485D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5684017A (en) * 1993-11-29 1997-11-04 Merrell Pharmaceuticals Inc. Benzenesulfonylimine derivatives as inhibitors of IL-1 action
ATE176225T1 (de) * 1993-11-29 1999-02-15 Merrell Pharma Inc Heterocyclische benzolsulfonyliminderivate als inhibitoren der il-1 wirkung
US5817496A (en) * 1994-07-07 1998-10-06 Pharmacia & Upjohn S.P.A. Recombinant kat enzyme from rat
FR2733233B1 (fr) * 1995-04-20 1997-05-30 Roussel Uclaf Nouveaux derives de quinoleine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US6025369A (en) * 1996-05-03 2000-02-15 The Board Of Regents Of The University Nebraska N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
EP1901744A2 (de) * 2005-06-28 2008-03-26 Bausch & Lomb Incorporated Zubereitungen mit arylazin, das mit einem carbonylsäureteil substituiert ist, zur erhöhung der aktivität von gelatinase a in okulären zellen
HU230366B1 (hu) 2010-06-29 2016-03-29 Szegedi Tudományegyetem Kinurénsavamid származékok alkalmazása Huntington-kór kezelésére
EP3414229B1 (de) 2016-02-09 2021-06-16 Pharmakea, Inc. Chinolin-lysyl-oxidase-like-2-inhibitoren und verwendungen davon
HUP1600179A2 (hu) 2016-03-04 2017-09-28 Univ Szegedi Új típusú C-3 szubsztituált kinurénsavszármazékok hatékonyabb neuroprotektív aktivitással
EP3427729A1 (de) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid zur behandlung von epileptischen erkrankungen, störungen oder zuständen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1207771A (en) * 1968-03-18 1970-10-07 Warner Lambert Pharmaceutical Anti-virally active quinoline derivatives
GB1334705A (en) * 1970-06-19 1973-10-24 Ici Ltd Pharmaceutical compositions containing kynurenic acid derivatives
US4156726A (en) * 1974-12-07 1979-05-29 Fisons Limited 4-Oxo-2-carboxyl quinoline derivatives used as antiallergic compounds

Also Published As

Publication number Publication date
CA1330660C (en) 1994-07-12
DK449588D0 (da) 1988-08-11
DE3880396T2 (de) 1993-10-21
EP0303387A1 (de) 1989-02-15
JPS6466167A (en) 1989-03-13
DE3880396D1 (de) 1993-05-27
EP0303387B1 (de) 1993-04-21
DK449588A (da) 1989-04-06
GB8719102D0 (en) 1987-09-16

Similar Documents

Publication Publication Date Title
ATE88344T1 (de) Zur behandlung von neurodegenerativen erkrankungen verwendbare kynurensaeurederivate.
IL92990A0 (en) Novel piperazinyl derivatives
HUT48589A (en) Process for production of new derivatives of substituated n-/1-hydroxi-4-piperidinil/-benzamid
EP0302525A3 (de) Chinolone als antibakterielles Mittel
NO873125L (no) Fremgangsmaate for fremstilling av antibakterielle forbindelser.
HUT57763A (en) Process for producing 2,9-disubstituted-4h-pyrido(1,2-a)pyrimidine-4-one derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUT53880A (en) Process for preparation of 3-phenyl-5,6-dilhydrobenz (c)-acridine-carboxylic-acids and carboxylic-acid derivatives and for manufacturing of pharmaceutical composition containing these compounds as active ingredient
NO901171L (no) Fremgangsmaate til fremstilling av substituerte azetidinylpyridonkarboksylsyrederivater.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties